Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia

1994 ◽  
Vol 8 (1-2) ◽  
pp. 149-158 ◽  
Author(s):  
H. Ichinose ◽  
T. Ohye ◽  
K. Fujita ◽  
F. Pantucek ◽  
K. Lange ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Amino Acid ◽  
Tyrosine Hydroxylase ◽  
Substantia Nigra ◽  
Acid Decarboxylase ◽  
Amino Acid Decarboxylase

scholarly journals Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Anouke van Rumund ◽  
Lukas Pavelka ◽  
Rianne A. J. Esselink ◽  
Ben P. M. Geurtz ◽  
Ron A. Wevers ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Enzyme Activity ◽  
Amino Acid ◽  
Therapeutic Effect ◽  
Disease Duration ◽  
Acid Decarboxylase ◽  
Amino Acid Decarboxylase ◽  
Decarboxylase Inhibitors ◽  
Higher Doses

AbstractPeripheral decarboxylase inhibitors (PDIs) prevent conversion of levodopa to dopamine in the blood by the enzyme aromatic L-amino acid decarboxylase (AADC). Alterations in enzyme activity may contribute to the required higher dosages of levodopa observed in many patients with Parkinson’s disease. We evaluated the effect of levodopa/PDI use on serum AADC enzyme activity. Serum AADC enzyme activity was evaluated in three independent cohorts of patients with Parkinson’s disease or parkinsonism (n = 301) and compared between patients on levodopa/PDI vs. patients not on this medication. AADC enzyme activity was elevated in 62% of patients on levodopa/PDI treatment, compared to 19% of patients not on levodopa/PDI (median 90 mU/L vs. 50 mU/L, p < 0.001). Patients with elevated AADC activity had longer disease duration and higher doses of levodopa/PDI. These findings may implicate that peripheral AADC induction could underlie a waning effect of levodopa, necessitating dose increases to maintain a sustained therapeutic effect.

scholarly journals Aromatic L‐Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease

2020 ◽  
Vol 35 (5) ◽  
pp. 851-858 ◽  
Author(s):  
John G. Nutt ◽  
Carolin Curtze ◽  
Amie Hiller ◽  
Shannon Anderson ◽  
Paul S. Larson ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Amino Acid ◽  
Acid Decarboxylase ◽  
Amino Acid Decarboxylase
Sign in / Sign up

Export Citation Format

Share Document